Responses to parliamentary questions
Question from Deputy John Clendennen - PQ 21311-26
Deputy Clendennen asked for an update on the accessibility of Belzutifan (Welireg) for the treatment of Von Hippel-Lindau syndrome. Read the HSE response.
From: Communications and public affairs
Published: March 2026
Updated: April 2026
Documents
Question from Deputy John Clendennen - PQ 21311-26
PDF, 164KB, 3 pages
Summary
To ask the Minister for Health for an update on the accessibility of Belzutifan (brand name Welireg) for the treatment of Von Hippel-Lindau syndrome; and if she will make a statement on the matter.
This is a beta version - your feedback will help us to improve it